Literature DB >> 2491458

Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial.

K Lauritsen1, B N Andersen, T Havelund, L S Laursen, J Hansen, J Eriksen, T Jørgensen, J Rask-Madsen.   

Abstract

One-hundred and seventy-one patients with endoscopically proven duodenal ulcers were allocated at random to double-blind treatment with 10 or 20 mg of omeprazole in the morning for up to 4 weeks. Patients completed the study if ulcer healing and pain relief had occurred at 2 weeks. A total of 155 patients completed the trial. Patients treated with 20 mg of omeprazole daily responded significantly more rapidly than those treated with 10 mg of omeprazole daily (P less than 0.001; Cochran-Mantel-Haenszel test covering both time points), cumulative healing rates at 2 and 4 weeks were 74% (58/78) and 91% (71/78), respectively. The corresponding rates in the group treated with 10 mg daily were 48% (39/81) and 75% (58/77). Pain relief was again more pronounced during treatment with the larger dose (P less than 0.05; stratified Wilcoxon test). No major clinical or biochemical side effects were noted. An omeprazole dose of 20 mg daily is preferable to a lower dose for the treatment of duodenal ulcer disease in the short term.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491458     DOI: 10.1111/j.1365-2036.1989.tb00191.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

Review 1.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

2.  The liver regenerative response elicited by antisecretory agents in partially hepatectomized rats: a comparison between omeprazole and famotidine.

Authors:  T Aono
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 3.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.